Argo Wealth Advisory LLC Takes $8.86 Million Position in AbbVie Inc. $ABBV

Key Points

• Argo Wealth Advisory LLC acquired a new stake of 38,785 shares in AbbVie valued at approximately $8.86 million, representing about 5.3% of Argo's holdings and making AbbVie its fifth-largest position.
• Senior insiders trimmed positions recently — EVP Perry C. Siatis sold 22,381 shares (~$5.15M) and SVP David Ryan Purdue sold 5,230 shares (~$1.22M) — leaving corporate insiders with just 0.06% ownership.
• AbbVie beat Q4 EPS expectations with revenue up 10%, set FY2026 guidance of 14.37–14.57 EPS, declared a $1.73 quarterly dividend (≈3.3% yield), and has near-term catalysts including a Phase 4 psoriasis study, a Phase 1 obesity trial (ABBV‑295) and a ~$650M deal for RC148.

Argo Wealth Advisory LLC acquired a new stake in AbbVie Inc. (NYSE:ABBV - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 38,785 shares of the company's stock, valued at approximately $8,862,000. AbbVie accounts for about 5.3% of Argo Wealth Advisory LLC's holdings, making the stock its 5th biggest holding.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in AbbVie by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company's stock valued at $41,155,601,000 after purchasing an additional 448,554 shares during the period. Legal & General Group Plc grew its position in shares of AbbVie by 4.3% during the 3rd quarter. Legal & General Group Plc now owns 12,004,084 shares of the company's stock worth $2,779,426,000 after buying an additional 493,420 shares during the period. Wellington Management Group LLP lifted its holdings in shares of AbbVie by 457.4% in the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company's stock worth $2,439,714,000 after purchasing an additional 8,646,424 shares in the last quarter. Amundi lifted its holdings in shares of AbbVie by 15.6% in the 3rd quarter. Amundi now owns 10,508,317 shares of the company's stock worth $2,418,909,000 after purchasing an additional 1,414,621 shares in the last quarter. Finally, Ameriprise Financial Inc. lifted its holdings in shares of AbbVie by 4.4% in the 3rd quarter. Ameriprise Financial Inc. now owns 9,675,877 shares of the company's stock worth $2,241,363,000 after purchasing an additional 408,426 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company's stock.

Insider Buying and Selling at AbbVie

In other news, EVP Perry C. Siatis sold 22,381 shares of the company's stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the transaction, the executive vice president directly owned 38,137 shares of the company's stock, valued at $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of the company's stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares in the company, valued at approximately $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.06% of the stock is owned by corporate insiders.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Motley Fool says ABBV is a "no‑brainer" buy on dips, highlighting its high dividend, cash flow and defensive pharma profile as reasons value/dividend investors should buy weakness. Why AbbVie Is a No-Brainer Stock to Buy on the Dip
• Positive Sentiment: AbbVie announced head‑to‑head Phase 4 psoriasis study updates — a potential near‑term clinical catalyst that could influence commercial positioning in immunology if results favor AbbVie’s therapy. AbbVie’s Head-to-Head Psoriasis Study Sets Up New Catalyst for ABBV Investors
• Positive Sentiment: AbbVie kicked off a Phase 1 trial for ABBV‑295 (obesity), signalling a strategic push into the high‑growth weight‑loss market where success could materially expand future revenue streams. AbbVie Steps Deeper Into Obesity Market With New Phase 1 ABBV-295 Trial
• Positive Sentiment: AbbVie paid an upfront of ~$650M to RemeGen for global rights to RC148 — a sizeable bolt‑on that strengthens the company’s oncology/rare disease pipeline (near‑term cash outflow but potential long‑term value). RemeGen Receives US$650 Million Upfront from AbbVie for RC148 Global Rights
• Neutral Sentiment: Evercore ISI trimmed its price target slightly ($233→$232) but kept an Outperform rating — a minor analyst tweak that maintains institutional conviction. Evercore ISI Tweaks AbbVie (ABBV) Estimates, Lowers Price Target Marginally
• Neutral Sentiment: Sector pieces and market reports (value stock roundups; thyroid‑eye‑disease market research) include AbbVie as a key player — these reinforce investor awareness but don't move fundamentals immediately. 1 Value Stock Worth Your Attention and 2 That Underwhelm Thyroid Eye Disease Treatment Market Research Report 2026
• Negative Sentiment: Technicals are a headwind: the stock is trading below both the 50‑day and 200‑day moving averages, which can pressure short‑term sentiment and limit upside until price recovers those levels.

AbbVie Price Performance

NYSE:ABBV opened at $209.00 on Friday. The business has a 50 day moving average of $219.30 and a 200 day moving average of $223.67. The company has a market capitalization of $369.55 billion, a price-to-earnings ratio of 88.56, a PEG ratio of 0.74 and a beta of 0.38. AbbVie Inc. has a 1-year low of $168.54 and a 1-year high of $244.81.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The firm had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. During the same quarter in the previous year, the company posted $2.16 earnings per share. The business's revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, sell-side analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.3%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie's dividend payout ratio is presently 293.22%.

Wall Street Analyst Weigh In

ABBV has been the topic of several recent analyst reports. The Goldman Sachs Group restated a "neutral" rating and set a $223.00 price objective on shares of AbbVie in a research note on Wednesday, January 28th. Wall Street Zen cut AbbVie from a "strong-buy" rating to a "buy" rating in a research note on Saturday, April 11th. Berenberg Bank set a $275.00 price objective on AbbVie in a research note on Tuesday, January 20th. Royal Bank Of Canada started coverage on AbbVie in a research note on Tuesday, February 24th. They issued an "outperform" rating and a $260.00 price objective on the stock. Finally, Evercore reduced their target price on AbbVie from $232.00 to $228.00 and set an "outperform" rating for the company in a report on Wednesday, February 4th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, AbbVie has a consensus rating of "Moderate Buy" and a consensus target price of $253.00.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.